We use cookies for a better user experience. Read our Privacy Policy

I Agree

Peptide Therapeutics Market

Peptide Therapeutics Market (Application: Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, and Renal) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Peptide Therapeutics Market Outlook 2031

  • The global peptide therapeutics market was valued at US$ 39.34 Bn in 2021
  • The global market is projected to grow at a CAGR of 8.8% from 2022 to 2031
  • The global peptide therapeutics market is anticipated to reach more than US$ 91.25 Bn by 2031

Analysts’ Viewpoint on Peptide Therapeutics Market Scenario

Sedentary lifestyle and unhealthy diet are leading to a surge in prevalence and incidence of chronic diseases. High incidence and prevalence of metabolic disorders is expected to drive the global peptide therapeutics market in the next few years. Growth in geriatric population across the globe is also expected to boost the global peptide therapeutics market. Peptides are now being widely used in therapeutic applications of cancer and chronic metabolic diseases due to advancements in technology. Rise in prevalence of cancer among the geriatric population is anticipated to increase the demand for new peptide therapeutics. Industry players are investing in research and development activities to introduce new peptide therapeutics in order to address this peptide therapeutics market demand.

Peptide Therapeutics Market

Peptide Therapeutics Market Introduction

Peptides are a combination of two or more amino acid monomers linked by amide bonds. Researchers have demonstrated that peptides are distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered peptides. In addition to the current definition of peptide, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. Peptides bind to specific cell surface receptors and receptor ligands, and help in the treatment of diseases by acting on the cell membrane. Therapeutic proteins and peptides are a growing class of drugs intended for clinical purposes owning to high bio-specificity. As per the peptide therapeutics market analysis, demand for peptide therapeutics has been rising significantly due to the decline in non-peptide chemical drugs available in the market.

Request a sample to get extensive insights into the Peptide Therapeutics Market

Impact of COVID-19 on Peptide Therapeutics market

The COVID-19 pandemic has had a positive impact on the global peptide therapeutics market growth. As of August 2022, 600 million infections and 6.4 million deaths were recorded across the world due to COVID-19. Peptide molecules are being used for the development of COVID-19 vaccine. Furthermore, government authorities of various countries have supported private players in the development and usage of COVID-19 vaccine. More than 21 peptide drugs are being used for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection. Peptide drugs are being considered a treatment option for COVID-19. Thus, key players in the market have reported an increase in revenue during the COVID-19 pandemic. However, the application of peptide therapeutics in oncology, metabolic disorders, etc. has been disrupted due to a shortage of drugs and supply chain issues along with the slow progress of clinical trials related to non-COVID-19 therapeutics.

Surge in Number of Cancer and Other Chronic Disease Patients to Drive Cancer Segment

In term of application, the cancer segment dominated the global market in 2021. Cancer is the leading cause of death globally. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2020. Chemotherapy, the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly, which negatively affects the normal cells in the body. Application of therapeutic peptides in cancer treatment has opened a promising avenue for future growth of the global peptide therapeutics market, as it has the ability to deliver drug with specific binding site. Peptide-based therapeutic vaccines have attracted attention as one of the effective treatments for tumor immunotherapy over the last few years. Rise in prevalence and incidence rate of other chronic conditions such as Alzheimer's, diabetes, cardiac diseases, and immune disorders, owing to the increase in geriatric population, is projected to propel the global peptide and Alzheimer's peptide therapeutics markets in the next few years.

Request a custom report on Peptide Therapeutics Market

Faster & Better Bioavailability and Quicker Onset Time Fueling Parenteral Segment

Based on route of administration, the global peptide therapeutics market has been classified into parenteral, oral, and others. The parenteral segment dominated the global peptide therapeutics market in 2021. Parenteral is the most common route of administration, as it ensures faster and better bioavailability, faster onset time, and better treatment outcomes. However, advancement in drug delivery technologies has led to a change in the trend of route of administration of therapeutic peptides.

Minimal Waste and High Peptide Purity & Yield Bolstering Liquid Phase Segment

Based on technology, the liquid phase segment held the largest share of the global peptide therapeutics market in 2021. Liquid phase synthesis is usually favored for peptides, which have less than 15 amino acids by length. Liquid phase peptide synthesis provides economies of scale for the manufacturing of peptides. Minimal waste and high peptide purity and yield are the key advantages of this technology.

Usage in Drugs for Treatment of Cancer and Tumors Augmenting Immunopeptides Segment

In terms of type of molecule, the immunopeptide segment is likely to grow at a rapid pace during the forecast period owing to the rise in usage of immunopeptides in drugs for the treatment of cancer and tumors. High prevalence of cancer and surge in incidence rate of new cancer cases are likely to drive the immunopeptides segment during the forecast period.

Stringent Quality Systems and Standards Requirements Driving In-house Segment

Based on API peptide type, the in-house segment dominated the global market in 2021. However, API manufacturers prefer to outsource peptides manufacturing to contract manufacturing organizations (CMOs) operating in the biosimilar market due to difficulties in manufacturing owing to the high quality standards implemented by regulatory authorities. For instance, Bachem and Peptisyntha provide end-to-end API peptides manufacturing, and possess expertise and high-end technology for various types of peptides. Nevertheless, the shift is likely to be gradual, as most API peptide companies still prefer to manufacture in-house due to stringent quality systems and standards requirements.

Regional Outlook of Global Peptide Therapeutics Market

North America is projected to dominate the global peptide therapeutics market during the forecast period. Well-established healthcare infrastructure, high priced peptide therapeutics drugs, and favorable reimbursement policies are augmenting the peptide therapeutics market growth in the region.

The market in Asia Pacific is anticipated to grow at a high CAGR during the forecast period due to the rise in prevalence of infectious diseases in the region. Increase in geriatric population and surge in healthcare expenditure are fueling the market in Asia Pacific. Furthermore, large patient pool and high demand for newer advanced therapies are key factors likely to boost the peptide therapeutics market in Asia Pacific.

Analysis of Key Players in Global Peptide Therapeutics market

The peptide therapeutics market report includes vital information about leading players in the global market. Companies are adopting product launch, divestiture, merger & acquisition, and partnership strategies to enhance their peptide therapeutics market share. Amgen, Inc., Bachem Holding AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global market.

Key Developments in Global Peptide Therapeutics market

  • In December 2022, ONL Therapeutics, Inc., a Michigan-based biopharmaceutical company that develops novel therapies, secured a US$ 46.9 Mn in a Series B financing round held in December 2020. This fund would be utilized to develop peptide manufacturing to prepare for IND application for phase 2 study.
  • In June 2022, EQT Life Sciences announced the second round of funding of US$ 25 Mn for Ariceum Therapeutics, a private biotech company developing a radiopharmaceutical product. The funding would enable Ariceum to develop satoreotide, its lead asset and proprietary peptide derivative.

Each of these players has been profiled in the peptide therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Peptide Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 39.34 Bn

Market Forecast Value in 2031

More than US$ 91.25 Bn

Growth Rate (CAGR) for 2022–2031

8.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Application
    • Cancer
    • Metabolic
    • CVD
    • Respiratory
    • GIT
    • Anti-infective
    • Dermatology
    • CNS
    • Renal
  • Route of Administration
    • Parenteral
    • Oral
  • Type
    • Innovative
    • Generic
  • Technology
    • Liquid Phase
    • Solid Phase
    • Hybrid Phase
  • Type of Molecule
    • Vasopressin
    • Somatostatin
    • Calcitonin
    • Natriuretic
  • API Peptide Type
    • In-house
    • CMO

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amgen, Inc.
  • Bachem Holding AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Peptide Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the anticipated CAGR of the peptide therapeutics market in the forecast period?

Peptide therapeutics market to expand at a CAGR of 7.9% from 2019 to 2027

What are the key driving factors for the growth of the peptide therapeutics market?

Peptide therapeutics market is driven by rise in adoption of hybrid technologies to achieve their economies of scale

Which region is expected to project the highest market share in the global peptide therapeutics market?

North America accounted for a major share of the global peptide therapeutics market

Which is the rising prominent segment in the peptide therapeutics market?

The cancer segment held the highest share on account of its increasing prevalence all across the world

Who are the key players in the global peptide therapeutics market?

Key players in the global peptide therapeutics market include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Pfizer Inc., Novartis AG, GlaxoSmithKline plc., F.Hoffmann-La Roche Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. White Space Analysis

    5.2. Porter’s Analysis

    5.3. Pipeline Analysis (Phase III)

    5.4. Peptide Drug Chemical Structure Trend Analysis

    5.5. Separation Media for Peptide Drug Manufacturing

    5.6. Covid-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecast, by Application

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Application, 2017–2031

        6.3.1. Cancer

        6.3.2. Metabolic

        6.3.3. CVD

        6.3.4. Respiratory

        6.3.5. GIT

        6.3.6. Anti-infective

        6.3.7. Dermatology

        6.3.8. CNS

        6.3.9. Renal

    6.4. Market Attractiveness Analysis, by Application

7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2031

        7.3.1. Parenteral

        7.3.2. Oral

    7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Peptide Therapeutics Market Analysis and Forecast, by Type

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Type, 2017–2031

        8.3.1. Innovative

        8.3.2. Generic

    8.4. Market Attractiveness Analysis, by Type

9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Technology, 2017–2031

        9.3.1. Liquid Phase

        9.3.2. Solid Phase

        9.3.3. Hybrid Phase

    9.4. Market Attractiveness Analysis, by Technology

10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule

    10.1. Introduction & Definition

    10.2. Key Findings / Developments

    10.3. Market Value Forecast, by Type of Molecule, 2017–2031

        10.3.1. Vasopressin

        10.3.2. Somatostatin

        10.3.3. Calcitonin

        10.3.4. Natriuretic

    10.4. Market Attractiveness Analysis, by Type of Molecule

11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type

    11.1. Introduction & Definition

    11.2. Key Findings / Developments

    11.3. Market Value Forecast, by API Peptide Type ,2017–2031

        11.3.1. In-house

        11.3.2. CMO

    11.4. Market Attractiveness Analysis, by API Peptide Type

12. Global Peptide Therapeutics Market Analysis and Forecast, by Region

    12.1. Key Findings

    12.2. Market Value Forecast, by Region

        12.2.1. North America

        12.2.2. Europe

        12.2.3. Asia Pacific

        12.2.4. Latin America

        12.2.5. Middle East & Africa

    12.3. Market Attractiveness Analysis, by Region

13. North America Peptide Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Application,2017–2031

        13.2.1. Cancer

        13.2.2. Metabolic

        13.2.3. CVD

        13.2.4. Respiratory

        13.2.5. GIT

        13.2.6. Anti-infective

        13.2.7. Dermatology

        13.2.8. CNS

        13.2.9. Renal

    13.3. Market Value Forecast, by End-user,2017–2031

        13.3.1. Parenteral

        13.3.2. Oral

    13.4. Market Value Forecast, by Type, 2017–2031

        13.4.1. Innovative

        13.4.2. Generic

    13.5. Market Value Forecast, by Technology, 2017–2031

        13.5.1. Liquid Phase

        13.5.2. Solid Phase

        13.5.3. Hybrid Phase

    13.6. Market Value Forecast, by Type of Molecule, 2017–2031

        13.6.1. Vasopressin

        13.6.2. Somatostatin

        13.6.3. Calcitonin

        13.6.4. Natriuretic

    13.7. Market Value Forecast, by API Peptide Type, 2017–2031

        13.7.1. In-house

        13.7.2. CMO

    13.8. Market Value Forecast, by Country, 2017–2031

        13.8.1. U.S.

        13.8.2. Canada

    13.9. Market Attractiveness Analysis

        13.9.1. By Application

        13.9.2. By Route of Administration

        13.9.3. By Type

        13.9.4. By Technology

        13.9.5. By Type of Molecule

        13.9.6. By API Peptide Type

        13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Application, 2017–2031

        14.2.1. Cancer

        14.2.2. Metabolic

        14.2.3. CVD

        14.2.4. Respiratory

        14.2.5. GIT

        14.2.6. Anti-infective

        14.2.7. Dermatology

        14.2.8. CNS

        14.2.9. Renal

    14.3. Market Value Forecast, by End-user, 2017–2031

        14.3.1. Parenteral

        14.3.2. Oral

    14.4. Market Value Forecast, by Type, 2017–2031

        14.4.1. Innovative

        14.4.2. Generic

    14.5. Market Value Forecast, by Technology, 2017–2031

        14.5.1. Liquid Phase

        14.5.2. Solid Phase

        14.5.3. Hybrid Phase

    14.6. Market Value Forecast, by Type of Molecule, 2017–2031

        14.6.1. Vasopressin

        14.6.2. Somatostatin

        14.6.3. Calcitonin

        14.6.4. Natriuretic

    14.7. Market Value Forecast, by API Peptide Type, 2017–2031

        14.7.1. In-house

        14.7.2. CMO

    14.8. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.8.1. Germany

        14.8.2. U.K.

        14.8.3. France

        14.8.4. Spain

        14.8.5. Italy

        14.8.6. Rest of Europe

    14.9. Market Attractiveness Analysis

        14.9.1. By Application

        14.9.2. By Route of Administration

        14.9.3. By Type

        14.9.4. By Technology

        14.9.5. By Type of Molecule

        14.9.6. By API Peptide Type

        14.9.7. By Country/Sub-region

15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Application, 2017–2031

        15.2.1. Cancer

        15.2.2. Metabolic

        15.2.3. CVD

        15.2.4. Respiratory

        15.2.5. GIT

        15.2.6. Anti-infective

        15.2.7. Dermatology

        15.2.8. CNS

        15.2.9. Renal

    15.3. Market Value Forecast, by End-user, 2017–2031

        15.3.1. Parenteral

        15.3.2. Oral

    15.4. Market Value Forecast, by Type, 2017–2031

        15.4.1. Innovative

        15.4.2. Generic

    15.5. Market Value Forecast, by Technology, 2017–2031

        15.5.1. Liquid Phase

        15.5.2. Solid Phase

        15.5.3. Hybrid Phase

    15.6. Market Value Forecast, by Type of Molecule, 2017–2031

        15.6.1. Vasopressin

        15.6.2. Somatostatin

        15.6.3. Calcitonin

        15.6.4. Natriuretic

    15.7. Market Value Forecast, by API Peptide Type, 2017–2031

        15.7.1. In-house

        15.7.2. CMO

    15.8. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.8.1. China

        15.8.2. Japan

        15.8.3. India

        15.8.4. Australia & New Zealand

        15.8.5. Rest of Asia Pacific

    15.9. Market Attractiveness Analysis

        15.9.1. By Application

        15.9.2. By Route of Administration

        15.9.3. By Type

        15.9.4. By Technology

        15.9.5. By Type of Molecule

        15.9.6. By API Peptide Type

        15.9.7. By Country/Sub-region

16. Latin America Peptide Therapeutics Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Market Value Forecast, by Application, 2017–2031

        16.2.1. Cancer

        16.2.2. Metabolic

        16.2.3. CVD

        16.2.4. Respiratory

        16.2.5. GIT

        16.2.6. Anti-infective

        16.2.7. Dermatology

        16.2.8. CNS

        16.2.9. Renal

    16.3. Market Value Forecast, by End-user, 2017–2031

        16.3.1. Parenteral

        16.3.2. Oral

    16.4. Market Value Forecast, by Type, 2017–2031

        16.4.1. Innovative

        16.4.2. Generic

    16.5. Market Value Forecast, by Technology,2017–2031

        16.5.1. Liquid Phase

        16.5.2. Solid Phase

        16.5.3. Hybrid Phase

    16.6. Market Value Forecast, by Type of Molecule, 2017–2031

        16.6.1. Vasopressin

        16.6.2. Somatostatin

        16.6.3. Calcitonin

        16.6.4. Natriuretic

    16.7. Market Value Forecast, by API Peptide Type, 2017–2031

        16.7.1. In-house

        16.7.2. CMO

    16.8. Market Value Forecast, by Country/Sub-region, 2017–2031

        16.8.1. Brazil

        16.8.2. Mexico

        16.8.3. Rest of Latin America

    16.9. Market Attractiveness Analysis

        16.9.1. By Application

        16.9.2. By Route of Administration

        16.9.3. By Type

        16.9.4. By Technology

        16.9.5. By Type of Molecule

        16.9.6. By API Peptide Type

        16.9.7. By Country/Sub-region

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

    17.1. Introduction

        17.1.1. Key Findings

    17.2. Market Value Forecast, by Application, 2017–2031

        17.2.1. Cancer

        17.2.2. Metabolic

        17.2.3. CVD

        17.2.4. Respiratory

        17.2.5. GIT

        17.2.6. Anti-infective

        17.2.7. Dermatology

        17.2.8. CNS

        17.2.9. Renal

    17.3. Market Value Forecast, by End-user, 2017–2031

        17.3.1. Parenteral

        17.3.2. Oral

    17.4. Market Value Forecast, by Type, 2017–2031

        17.4.1. Innovative

        17.4.2. Generic

    17.5. Market Value Forecast, by Technology, 2017–2031

        17.5.1. Liquid Phase

        17.5.2. Solid Phase

        17.5.3. Hybrid Phase

    17.6. Market Value Forecast, by Type of Molecule, 2017–2031

        17.6.1. Vasopressin

        17.6.2. Somatostatin

        17.6.3. Calcitonin

        17.6.4. Natriuretic

    17.7. Market Value Forecast, by API Peptide Type, 2017–2031

        17.7.1. In-house

        17.7.2. CMO

    17.8. Market Value Forecast, by Country/Sub-region, 2017–2031

        17.8.1. GCC Countries

        17.8.2. South Africa

        17.8.3. Rest of Middle East & Africa

    17.9. Market Attractiveness Analysis

        17.9.1. By Application

        17.9.2. By Route of Administration

        17.9.3. By Type

        17.9.4. By Technology

        17.9.5. By Type of Molecule

        17.9.6. By API Peptide Type

        17.9.7. By Country/Sub-region

18. Competition Landscape

    18.1. Market Player – Competition Matrix (by tier and size of companies)

    18.2. Market Share Analysis, by Company, 2021

    18.3. Company Profiles

        18.3.1. Amgen, Inc.

            18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.1.2. Product Portfolio

            18.3.1.3. SWOT Analysis

            18.3.1.4. Strategic Overview

        18.3.2. Bachem Holding AG

            18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.2.2. Product Portfolio

            18.3.2.3. SWOT Analysis

            18.3.2.4. Strategic Overview

        18.3.3. Eli Lilly and Company

            18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.3.2. Product Portfolio

            18.3.3.3. SWOT Analysis

            18.3.3.4. Strategic Overview

        18.3.4. F. Hoffmann-La Roche Ltd.

            18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.4.2. Product Portfolio

            18.3.4.3. SWOT Analysis

            18.3.4.4. Strategic Overview

        18.3.5. GlaxoSmithKline plc

            18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.5.2. Product Portfolio

            18.3.5.3. SWOT Analysis

            18.3.5.4. Strategic Overview

        18.3.6. Novartis AG

            18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.6.2. Product Portfolio

            18.3.6.3. SWOT Analysis

            18.3.6.4. Strategic Overview

        18.3.7. Pfizer, Inc.

            18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.7.2. Product Portfolio

            18.3.7.3. SWOT Analysis

            18.3.7.4. Strategic Overview

        18.3.8. Sanofi

            18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.8.2. Product Portfolio

            18.3.8.3. SWOT Analysis

            18.3.8.4. Strategic Overview

        18.3.9. Takeda Pharmaceutical Company Limited

            18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.9.2. Product Portfolio

            18.3.9.3. SWOT Analysis

            18.3.9.4. Strategic Overview

        18.3.10. Teva Pharmaceutical Industries Ltd.

            18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.10.2. Product Portfolio

            18.3.10.3. SWOT Analysis

            18.3.10.4. Strategic Overview

List of Table

Table 01: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 02: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2021–2031

Table 03: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 04: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 05: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 06: Global API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 07: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Region, 2021–2031

Table 08: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2021–2031

Table 09: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 10: North America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 11: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 12: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 13: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 14: North America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 15: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 16: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 17: Europe Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 18: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 19: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 20: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 21: Europe API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 22: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 23: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 24: Asia Pacific Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 25: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 26: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 27: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 28: Asia Pacific API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 29: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 30: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 31: Latin America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 32: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 33: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 34: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 35: Latin America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 36: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 37: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2021–2031

Table 38: Middle East & Africa Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2021–2031

Table 39: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

Table 40: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2021–2031

Table 41: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2021–2031

Table 42: Middle East & Africa API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2021–2031

List of Figures

Figure 01: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2021 and 2031

Figure 02: Global Cancer Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 03: Global Metabolic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 04: Global CVD Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 05: Global Respiratory Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 06: Global GIT Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 07: Global Anti-infective Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 08: Global Dermatology Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 09: Global CNS Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 10: Global Renal Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 11: Global Others Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 12: Global Peptide Therapeutics Market Attractiveness Analysis, by Application, 2022–2031

Figure 13: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 14: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Parenteral, 2021–2031

Figure 15: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Oral, 2021–2031

Figure 16: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Others, 2021–2031

Figure 17: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 18: Global Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031

Figure 19: Global Innovative Peptide Therapeutics Market Size (US$ Mn), 2021–2031

Figure 20: Global Generic Peptide Therapeutics Market Size (US$ Mn), 2021–2031

Figure 21: Global Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 21: Global Peptide Therapeutics Market Value Share Analysis, by Technology, 2021 and 2031

Figure 22: Global Liquid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 23: Global Solid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 24: Global Hybrid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 25: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 26: Global Peptide Therapeutics Market Value Share Analysis, by Type of Molecules, 2021 and 2031

Figure 27: Global Vasopressin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 28: Global Somatostatins Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 29: Global Calcitonin Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 30: Global Immunopeptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 31: Global Natriuretic Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 32: Global Other Peptides Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 33: Global Peptide Therapeutics Market Attractiveness Analysis, by Type of Molecule, 2022–2031

Figure 34: Global API Peptide Therapeutics Market Value Share Analysis, by Type, 2021 and 2031

Figure 35: Global In-house Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 36: Global CMO Peptide Therapeutics Market Size Forecast (US$ Mn), 2021–2031

Figure 37: Global API Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 38: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 39: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 40: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 41: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 42: MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 43: Global Peptide Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

Figure 44: U.S. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 45: Canada Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 46: North America Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 47: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 48: North America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 49: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 50: Germany Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 51: U.K. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 52: France Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 53: Italy Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 54: Spain Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 55: Rest of Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 56: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 57: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 58: Europe Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 59: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 60: Japan Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 61: China Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 62: India Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 63: Rest of APAC Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 64: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 65: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 66: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 67: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 68: Brazil Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 69: Mexico Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 70: Rest of LATAM Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 71: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 72: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 73: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 74: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 75: South Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 76: Saudi Arabia Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 77: Rest of MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2021–2031

Figure 78: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 79: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 80: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type, 2022–2031

Figure 81: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology, 2022–2031

Figure 82: Peptide Therapeutics Market Share Analysis, by Company, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

457

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved